Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome—positive acute lymphoblastic leukemia
OG Ottmann, RA Larson, HM Kantarjian, PD Le Coutre… - Leukemia, 2013 - nature.com
The t (9; 22)(q34; q11) translocation, known as the Philadelphia chromosome (Ph), is
present in B15–30% of adult patients with acute lymphoblastic leuremia (ALL). 1 This …
present in B15–30% of adult patients with acute lymphoblastic leuremia (ALL). 1 This …
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or-intolerant Ph+ CML or relapsed/refractory Ph+ ALL
A Tojo, K Usuki, A Urabe, Y Maeda… - International journal of …, 2009 - Springer
Nilotinib is a second-generation BCR-ABL kinase inhibitor with improved potency and
selectivity compared to imatinib. A Phase I/II dose-escalation study was designed to …
selectivity compared to imatinib. A Phase I/II dose-escalation study was designed to …
Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance
Abstract BACKGROUND: INNO‐406, a dual v‐abl Abelson murine leukemia viral oncogene
homolog (Abl)/v‐yes‐1 Yamaguchi sarcoma viral‐related oncogene homolog (Lyn) tyrosine …
homolog (Abl)/v‐yes‐1 Yamaguchi sarcoma viral‐related oncogene homolog (Lyn) tyrosine …
A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl
HG Choi, P Ren, F Adrian, F Sun, HS Lee… - Journal of medicinal …, 2010 - ACS Publications
The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to
override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we …
override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we …